Baseline PSA was a stronger predictor of prostate cancer risk than race and family history of prostate cancer. Median PSA levels ranged from ~0.4 to 0.7 ng/mL in patients in their 40s and from ~0.7 to 1 ng/mL in patients in their 50s. 38. The prevalence of prostate cancer is low among patients aged 40 to 45 years.

Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.

While the benefits of PSA-based prostate cancer screening have been evaluated in randomized-controlled trials, the literature supporting the efficacy of digital rectal exam (DRE), PSA derivatives and isoforms (e.g. free PSA, -2proPSA, prostate health index, hK2, PSA velocity or PSA doubling time) and novel urinary markers and biomarkers (e.g ...

2023年4月25日 · Conclusions: Prostate-specific antigen (PSA)-based prostate cancer screening in combination with shared decision-making (SDM) is recommended. Current data regarding risk from population-based cohorts provide a basis for longer screening in-tervals and tailored screening, and the use of available online risk calculators is encouraged.

Prostate-specific antigen (PSA)-based prostate cancer screening in combination with shared decision-making (SDM) is recommended. Current data regarding risk from population-based cohorts provide a basis for longer screening intervals and tailored screening, and the use of available online risk calculators is encouraged.

2023年7月1日 · Part I of this guideline series presented recommendations on PSA-based prostate cancer screening, emphasizing shared decision-making (SDM) and tailored risk evaluations to guide the decision for a prostate biopsy.

2023年4月25日 · Prostate-specific antigen (PSA)-based prostate cancer screening in combination with shared decision-making (SDM) is recommended. Current data regarding risk from population-based cohorts provide a basis for longer screening intervals and tailored screening, and the use of available online risk calcu …

The Panel recommended shared decision-making for men age 55 to 69 years considering PSA-based screening, a target age group for whom benefits may outweigh harms. Outside this age range, PSA-based screening as a routine could not be …

2024年7月4日 · Prostate-specific antigen (PSA)-based prostate cancer screening in combination with shared decision-making (SDM) is recommended. Current data regarding risk from population-based cohorts provide a basis for longer screening intervals and tailored screening, and the use of available online risk calculators is encouraged. Background

2023年4月24日 · When screening for prostate cancer, clinicians should use PSA as the first screening test. (Strong, A)

前列腺癌治疗方式，2024年5月3日至5月6日召开了美国泌尿外科协会（aua）年会。aua/放射肿瘤学会（astro）/泌尿肿瘤学会（suo）共同制定了2024版前列腺癌治疗指南，其中前列腺癌根治性手术后生化复发（bc

2 天之前 · SES AUA 2025 outcomes of black men undergoing PSA screening, ... Georgia Cancer Center, Wellstar MCG Health, @zklaassen_md on Twitter during the American Urological Association (SESAUA) 2025 Annual Meeting, Nashville, TN, Wed, Mar 12 – Sat, Mar 15, 2025. About UroToday; Journals;

2013年8月1日 · Therefore, this document focuses only on the efficacy of PSA screening for the early detection of prostate cancer with the specific intent to reduce prostate cancer mortality and not secondary tests often used after screening to determine the need for a prostate biopsy or a repeat prostate biopsy (eg PSA isoforms, PCA3, imaging).

2023年6月14日 · The American Urological Association (AUA) and Society of Urologic Oncology (SUO) recently issued guidelines for early prostate cancer detection that include recommendations related to...

Despite the low sensitivity and specificity of DRE, the EAU guidelines state, “Men requesting an early diagnosis should be given a PSA test and undergo a DRE,” as in 18% of cases prostate cancer is detected by suspect DRE alone, and an elevated PSA with abnormal DRE doubles the risk of positive prostate biopsy. 20 While the AUA/SUO ...

With the exception of prostate-specific antigen (PSA)-based prostate cancer screening, there was minimal evidence to assess the outcomes of interest for other tests. The quality of evidence for the benefits of screening was moderate, and evidence for …

When screening for prostate cancer, clinicians should use PSA as the first screening test. For people with a newly elevated PSA, clinicians should repeat the PSA prior to a secondary biomarker, imaging, or biopsy. Clinicians may begin prostate cancer screening and offer a baseline PSA test to people between ages 45 to 50 years.

Purpose: This guideline addresses prostate cancer early detection for the purpose of reducing prostate cancer mortality with the intended user as the urologist. This document does not make a distinction between early detection and screening for prostate cancer.

La AUA cree que todos los hombres, con una expectativa de vida de 10 años más, deberían tener una referencia realizandose una prueba de PSA a la edad de 40. Los médicos deberían determinar escaneos a ciertos intervalos de tiempo para cada paciente basandose en los resultados de la PSA (y en ocasiones, en su cambio a través del tiempo).

This guideline covers advanced prostate cancer, including disease stages that range from prostate-specific antigen (PSA) recurrence after exhaustion of local treatment options to widespread metastatic disease. Methodology. The systematic review utilized to inform this guideline was conducted by an independent methodological consultant.